Genfit swallows Versantis in €105m deal
Through the acquisition of Versantis for €40m upfront and further €65m in milestones, Genfit SA has added three clinical and preclinical candidates to its liver drug portfolio.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
Entries by Thomas Gabrielczyk
Food specialist Standing Ovation SA raises €12m
Foodtech startup Standing Ovation SA has closed an oversubscribed €12m Series A financing round led by Astanor Ventures.
HeartBeat.bio inks partnership with Molecular Devices
HeartBeat.bio and Molecular Devices announce collaboration to automate and scale cardiac organoids for high-throughput drug discovery screening
Mobile app recognises COVID-19 infection
Dutch researchers report they could detect a COVID-19 infection with better sensitivity than antigen tests by a mobile app that uses AI to analyse voice recordings.
Pleco Therapeutics raises €17.3m in Series A
Dutch Pleco Therapeutics BV has raised €17.3m in a Series A financing to push its lead candidate in acute myeloid leukaemia to market approval.
Emergence Therapeutics licences Synaffix platform
Synaffix B.V. and Emergence Therapeutics AG have entered into a licensing agreement of up to $360m to find ADCs directed against target molecules from Emergence.
Abivax SA bags €49.2m to push ABX-464
Paris-based Abivax SA has cashed in €49.2m in an oversubscribed financing with top-tier US and European biotech investors.
BioEcho Life Sciences launches US subsidiary
German nucleic acid extraction specialist BioEcho Life Sciences has opened a subsidiary in Boston to supply the huge US-american market.
Belgian researchers create extraembryonic mesoderm cells
Researchers from KU Leuven for the first time have produced human cells able to mimic the molecular mechanisms of early human embryogenesis and related defects.
SARS-CoV-2 infection triggers chronic fatigue syndrome
A small prospective study among mid-aged people has demonstrated that a mild SARS-CoV-2 infection triggers ME/CF in 50% of the study population.<button lang="en-GB" aria-description="Klicken, um Alternative zu verwenden">
</button>